Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

776 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation.
Weinstock-Guttman B, Hagemeier J, Kavak KS, Saini V, Patrick K, Ramasamy DP, Nadeem M, Carl E, Hojnacki D, Zivadinov R. Weinstock-Guttman B, et al. Among authors: patrick k. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):937-43. doi: 10.1136/jnnp-2015-312221. Epub 2016 Jan 18. J Neurol Neurosurg Psychiatry. 2016. PMID: 26780938 Clinical Trial.
Dalfampridine benefits ambulation but not cognition in multiple sclerosis.
Satchidanand N, Drake A, Smerbeck A, Hojnacki D, Kolb C, Patrick K, Weinstock-Guttman B, Motl R, Benedict RH. Satchidanand N, et al. Among authors: patrick k. Mult Scler. 2020 Jan;26(1):91-98. doi: 10.1177/1352458518815795. Epub 2018 Dec 19. Mult Scler. 2020. PMID: 30566030 Clinical Trial.
Risk of bone loss in men with multiple sclerosis.
Weinstock-Guttman B, Gallagher E, Baier M, Green L, Feichter J, Patrick K, Miller C, Wrest K, Ramanathan M. Weinstock-Guttman B, et al. Among authors: patrick k. Mult Scler. 2004 Apr;10(2):170-5. doi: 10.1191/1352458504ms993oa. Mult Scler. 2004. PMID: 15124763
Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis.
Weinstock-Guttman B, Zivadinov R, Tamaño-Blanco M, Abdelrahman N, Badgett D, Durfee J, Hussein S, Feichter J, Patrick K, Benedict R, Ramanathan M. Weinstock-Guttman B, et al. Among authors: patrick k. J Neuroimmunol. 2007 Aug;188(1-2):167-74. doi: 10.1016/j.jneuroim.2007.06.003. Epub 2007 Jun 28. J Neuroimmunol. 2007. PMID: 17602759
Genomic effects of IFN-beta in multiple sclerosis patients.
Weinstock-Guttman B, Badgett D, Patrick K, Hartrich L, Santos R, Hall D, Baier M, Feichter J, Ramanathan M. Weinstock-Guttman B, et al. Among authors: patrick k. J Immunol. 2003 Sep 1;171(5):2694-702. doi: 10.4049/jimmunol.171.5.2694. J Immunol. 2003. PMID: 12928423
Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
Weinstock-Guttman B, Bhasi K, Badgett D, Tamaño-Blanco M, Minhas M, Feichter J, Patrick K, Munschauer F, Bakshi R, Ramanathan M. Weinstock-Guttman B, et al. Among authors: patrick k. J Neuroimmunol. 2008 Dec 15;205(1-2):113-25. doi: 10.1016/j.jneuroim.2008.09.004. Epub 2008 Oct 23. J Neuroimmunol. 2008. PMID: 18950872 Clinical Trial.
776 results